Israel News App
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) – Novartis
Written by
admin
in
6. Business
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Novartis
US FDA approves Novartis’ drug for skin disease
Yahoo
FDA’s Approval of Remibrutinib for CSU,…
Continue Reading